<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083484</url>
  </required_header>
  <id_info>
    <org_study_id>3475-030</org_study_id>
    <nct_id>NCT02083484</nct_id>
  </id_info>
  <brief_title>Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)</brief_title>
  <official_title>Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for participants who have progressed after prior
      systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1
      (BRAF) inhibitor or mitogen-activated protein kinase (MEK) enzyme inhibitor when indicated.
      Participants cannot be eligible for or have participated in any pembrolizumab (MK-3475)
      clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Unresectable (Stage III) or metastatic melanoma

          -  Failed or progressed on standard of care systemic therapy including ipilimumab

          -  Willing to sign Informed Consent

          -  Eastern Cooperative Oncology Group Performance status of 0 or 1

          -  Female participants of childbearing potential must be willing to use adequate
             contraception or be surgically sterile, or abstain from heterosexual activity
             starting with the first dose of treatment through at least 120 days after the last
             dose of pembrolizumab

          -  Male participants must agree to use an adequate method of contraception starting with
             the first dose of treatment through 120 days after the last dose of pembrolizumab

          -  Adequate organ function

        Exclusion criteria:

          -  Eligible for an accessible pembrolizumab clinical study or previously participated in
             a pembrolizumab clinical study

          -  Eligible for treatment with a marketed BRAF inhibitor or MEK inhibitor

          -  Not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or
             better due to prior chemotherapy, radioactive, or biological cancer therapy
             (including monoclonal antibodies)

          -  Not recovered from minor or major surgery and less than 4 weeks from major surgery

          -  History of life-threatening or severe immune-related adverse events on treatment with
             another immunotherapy

          -  Expected to require any other form of systemic antineoplastic therapy while receiving
             pembrolizumab

          -  History of clinically severe autoimmune disease (e.g., requires chronic
             immunosuppressive therapy)

          -  History of pneumonitis, organ transplant, human immunodeficiency virus (HIV), active
             hepatitis B or hepatitis C

          -  Active central nervous system metastases, carcinomatous meningitis, untreated brain
             metastases

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of treatment with pembrolizumab

          -  Active infection requiring systemic therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Idis</last_name>
    <phone>1-855-478-4347</phone>
    <email>mk3475us@idispharma.com</email>
  </overall_contact>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
